DSIP: research, preparation & references

At a glance

A peptide investigated in sleep physiology and stress-related signaling.

This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.

How it works

Delta sleep-inducing peptide has been studied as a possible modulator of sleep and stress responses. Its name describes a research history, not a guarantee that it reliably induces restorative sleep.^[2]^[7]^[8]

Potential benefits & side effects

Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.

Potential benefits & research findings

The source discusses sleep recordings and clinical observations. Study size, reproducibility and adverse-event reporting should guide interpretation of any potential benefit.^[2]^[3]^[8]

Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.

Side effects & evidence limitations

Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of DSIP.

Source-reported adverse effects and cautions

Remarkably safe profile: animal studies found no lethal dose even at extremely high doses; human studies report only mild, transient side effects (occasional headache or nausea)^[1]^[8].

Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.

Editorial responsibility: Pep Science editorial desk
Last independent review: Not yet recorded

Editorial standards & corrections

SPECIFICATIONS & SOURCE SCHEDULES

Explore a vial size

Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.

Showing 10 mg · 1 source tables

Source-derived research information. Table phases retain the source’s actual duration; open-ended phases are not converted into a fixed eight-week course. Review the original study before interpreting a schedule.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week 1Week 2Week 3Weeks 4–8

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 1	100 mcg	3 units (0.03 mL)
Week 2	150 mcg	5 units (0.05 mL)
Week 3	200 mcg	6 units (0.06 mL)
Weeks 4–8	250–300 mcg	8–9 units (0.08–0.09 mL)

Frequency: Inject once daily subcutaneously in the evening, approximately 30–60 minutes before bedtime[4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Additional schedule context & duration

Concise summary of the once-daily evening regimen.

Goal: Support improved sleep quality, enhanced delta-wave (slow-wave) sleep, and stress modulation over time^[2]^[3].
Schedule: Daily subcutaneous injections in the evening for 8–12 weeks.
Dose Range: 100–300 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested nightly titration approach.

Start: 100 mcg nightly; increase by ~50 mcg every 1–2 weeks as tolerated.
Target: 250–300 mcg nightly by Weeks 4–8.
Frequency: Once per day (subcutaneous), 30–60 minutes before bedtime.
Cycle Length: 8–12 weeks; consider a break after the cycle.
Timing: Evening dosing to align with natural sleep onset; rotate injection sites.

Read this source protocol ↗ · View cited documents ↓

Preparation

Preparation and stability depend on the formulation, diluent, container and handling. The source-specific notes below apply to the selected record.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[5].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[6]^[10].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[6].
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[10].
Using a 30- or 50-unit insulin syringe improves accuracy when measuring small volumes (3–9 units).

Understanding reconstitution ↗Storage principles ↗

Materials & quantity planning

Source materials checklist · 10 mg

Plan based on an 8–12 week nightly protocol with gradual titration.

Peptide Vials (DSIP, 10 mg each):
- 8 weeks ≈ 1 vial (10 mg supports ~33–100 doses at 100–300 mcg)
- 12 weeks ≈ 2 vials
Insulin Syringes (30- or 50-unit recommended for small volumes):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes

Calculate a phased quantity

Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.

Phase 1 · weeksDoses / weekmcg / dose

Complete each phase to calculate totals.

Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.

FOLLOW THE EVIDENCE

References & further reading

Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.

01
Source document
European Journal of Anaesthesiology — Delta sleep-inducing peptide: discovery, structure, and pharmacological overview (opens in a new tab)
journals.lww.com
Back to overview ↑
02
Research publication
Neuroscience & Biobehavioral Reviews (PubMed) — Delta-sleep-inducing peptide (DSIP): a review of sleep-promoting and neuromodulatory effects (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
03
Research publication
European Neurology (PubMed) — Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
04
Research publication
European Neurology (PubMed) — DSIP in insomnia: timing and frequency of administration in clinical trials (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
05
Source document
Tocris Bioscience — Stability and storage guidelines for research peptides (opens in a new tab)
www.tocris.com
Back to overview ↑
06
Public health resource
MedlinePlus (U.S. National Library of Medicine) — Subcutaneous (SQ) injections: technique, site selection, and procedure (opens in a new tab)
medlineplus.gov
Back to overview ↑
07
Source document
Frontiers in Pharmacology — DSIP fusion peptides crossing the blood-brain barrier and efficacy in insomnia models (opens in a new tab)
www.frontiersin.org
Back to overview ↑
08
Research publication
European Neurology (PubMed) — Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic pain episodes (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
09
Research publication
European Neurology (PubMed) — DSIP in the treatment of withdrawal syndromes from alcohol and opiates (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
10
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection: site rotation and best practices (opens in a new tab)
www.hopkinsarthritis.org
Back to overview ↑
11
Research publication
European Neurology (PubMed) — Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients (double-blind study) (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
12
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site guidance) (opens in a new tab)
www.cdc.gov
Back to overview ↑
13
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑
14
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)
pmc.ncbi.nlm.nih.gov
Back to overview ↑
15
Research publication
Schoenenberger GA, Monnier M (1977) — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
16
Research publication
European Journal of Anaesthesiology (2001) — Delta sleep-inducing peptide: editorial review of mechanisms and clinical context (opens in a new tab)
doi.org
Back to overview ↑
17
Research publication
Schneider-Helmert D, Schoenenberger GA (1983) — Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
18
Research publication
Sudakov KV et al. (2004) — Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
19
Research publication
Schneider-Helmert D (1981) — Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
20
Research publication
Graf MV, Kastin AJ (1984) — Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
21
Research publication
Iyer KS et al. (1988) — Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
22
Research publication
Manning MC et al. (2010) — Stability of protein pharmaceuticals: an update. Pharm Res (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
23
Research publication
Wang W (2000) — Lyophilization and development of solid protein pharmaceuticals. Int J Pharm (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
24
Research publication
Yehuda S, Carasso RL (1988) — DSIP: brain mechanisms and function. Int J Neurosci (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
25
Research publication
Khvatova EM et al. (2003) — Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
26
Public health resource
NCBI Bookshelf — Medication Administration: Subcutaneous Injections (Open RN Nursing Skills) (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑